Immunohistochemistry in Human Tissues
Immunohistochemistry (IHC) is the most widely used technique in histopathological diagnosis and research for detection of proteins in tissues and cells. Today, IHC can be applied in a high-throughput fashion for studying proteins using Tissue Microarrays (TMAs).
Immunohistochemistry and the Human Protein Atlas
In the Human Protein Atlas project, Triple A Polyclonal antibodies have been designed to analyze all human proteins using IHC and TMAs1,2. All resulting tissue and cell images are publicly available on the Human Protein Atlas web portal (proteinatlas.org)3,4. In total, more than 500 high resolution IHC images from human tissue samples are presented for each antibody.
The Human Protein Atlas project has created a complete map of protein expression in all major organs and tissues in the human body1,2. To accomplish this, highly specific antibodies directed against all of the human proteins were generated and subsequent protein profiling was established in a multitude of tissues and cells.
The Human Protein Atlas (www. proteinatlas.org) consists of six separate parts, each using a particular approach to study the spatial distribution of human proteins; the Tissue Atlas, the Cell Atlas, the Pathology Atlas , the Brain Atlas, the Blood Atlas showing the impact of protein levels for survival of patients with cancer and the Single Cell Type Atlas.
Tissue and Pathology Atlases
Each antibody in the Human Protein Atlas project generates more than 500 high-resolution images corresponding to normal and cancer tissues. In this manner, an IHC atlas for tissue expression and localization is built for each protein, divided into a Tissue Atlas and a Pathology Atlas.
Samples from up to 44 different human normal tissue types and 20 different types of cancer have been used. Normal tissues are sampled from 144 different individuals and cancer tissues are derived from 216 unique tumors3,4.
IHC method in the Human Protein Atlas Project
Within the Human Protein Atlas project, antibody production and analysis is performed in a high-throughput fashion6, with the immunohistochemistry procedure highly automated and performed under standardized conditions.
Tissue Microarrays
The TMA technology provides an automated array-based high- throughput technique in which as many as 1,000 paraffin embedded tissue samples can be brought into one paraffin block in an array format. This allows for proteinexpression profiling in large scale.
TMAs are constructed by extracting cylinders of formalin fixed, paraffin embedded tissue from donor blocks with a sharp punch and assembling them into a recipient block with properly sized holes in a grid pattern5 (Figure 1). From each array block, approximately 250 sections can be achieved and prepared for IHC analysis.

Antigen Retrieval and Staining
For antigen retrieval, Heat Induced Epitope Retrieveal (HIER) is performed in citrate buffer at pH 6, using a pressure boiler. The antibodies are diluted using a dilution robot and staining is performed in an Autostainer.
A Horse Radish Peroxidase (HRP)-conjugated combination of a secondary antibody and a polymer together with the chromogen diaminobenzidine (DAB) are used for detection.
The specific binding of an antibody to its corresponding antigen results in a brown staining (Figure 2). The tissue section is counterstained with hematoxylin. Hematoxylin staining is unspecific and results in a blue coloring of both cells and extracellular material.

Figure 2: Schematic figure of the immunohistochemical staining reaction.
Triple A Polyclonals and PrecisA Monoclonals are used as primary antibodies. The secondary antibody is labeled with the enzyme HRP which forms a complex with the substrate H2O2. In the presence of the chromogen DAB, a brown color is visible using light microscopy. The signal can be amplified using an enzyme- linked dextran polymer.
Evaluation and Validation
Antibody Approval
The optimal dilution is determined and the antibodies are approved based on a comparison of staining pattern, available information from gene and protein public databases, as well as inhouse technical validation such as protein arrays, RNA sequencing information and Western Blots.
Image Annotation
All immunostained slides are scanned to generate resolution images.The images representing immunostained tissue sections are analyzed and annotated manually by trained pathologists. All images and annotations are published and freely available at the Human Protein Atlas portal (proteinatlas. org).
Subcellular Analysis Using IHC
Data on the localization of proteins within a cell provides important information as to what basic functions a protein may have as well as a possibility to map possible other interacting proteins.
The established golden standard for visualizing proteins at a subcellular level is immunocytochemistry- immunofluorescence (ICC-IF).
The vast majority of studies based on ICC-IF are performed on cultured cells though, with the disadvantage of not being able to analyze cells in their natural tissue context.
Figure 3 shows that IHC can be used to localize proteins at a subcellular level.

Figure 3: IHC stainings showing the subcellular location of different proteins. (A-C) IHC for recognition of cell membrane-related proteins. (D-F) IHC on proteins expressed in different cytoplasmic compartments. (G-I ) IHC on proteins expressed in different nuclear structures. Recognition of target antigen is represented by brown color.
References
- Uhlén M. et al. Tissue-based map of the human proteome. Science 2015 347(6220):1260419
- Uhlén M. et al. A pathology atlas of the human cancer transcriptome. Science. 2017 357(6352)
- Pontén F et al. The Human Protein Atlas - a tool for pathology. J Pathology 2008 216(4):387-93
- Kampf C et al. Antibody-based tissue profiling as a tool in clinical proteomics. Clin Proteomics 2004 1(3-4):285-300.
- Kampf C et al. Production of tissue microarrays, immunohistochemistry staining and digitalization within the human protein atlas. J Vis Exp. 2012 May 31;(63).
- Uhlén M et al Towards a knowledge-based Human Protein Atlas. Nat Biotechnol 2010 28(12):1248-50.